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Abstract p53 is stabilized in response to DNA damaging stress.
This stabilization is thought to result from phosphorylation in the
N-terminus of p53, which inhibits p53:MDM2 binding, and
prevents MDM2 from promoting p53 ubiquitination. In this
report, the DNA alkylating agents mitomycin C (MMC) and
methylmethane sulfonate (MMS), as well as UV radiation,
stabilized p53 in a manner independent of phosphorylation in p53
N-terminus. This stabilization coincided with decreased levels of
MDM2 mRNA and protein, and a corresponding decrease in p53
ubiquitination. Importantly, MDM2 overexpression inhibited the
stabilization of p53 and decrease in ubiquitination following
MMC, MMS, and UV treatment. This indicates that down-
regulation of MDM2 contributes to the stabilization of p53 in
response to these agents. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The tumor suppressor p53 plays an important role in re-
sponse to DNA damage by serving as a cell cycle check point
determinant [1,2]. Wild-type p53 levels are low in most normal
cells due to a short protein half-life [3,4]. However, the p53
protein is stabilized and accumulates in the nucleus upon ex-
posure to various DNA damaging agents [5,6]. The e¡ect of
increasing p53 is to stop cell proliferation, through either a G1
cell cycle arrest, or apoptotic cell death [2]. These activities are
mediated by proteins such as p21 and bax, whose genes are
transcriptionally activated by p53 [7^9].
The mechanism by which p53 is stabilized in response to
DNA damage has not been fully clari¢ed. p53 degradation
occurs through the ubiquitin proteolysis pathway, and factors
which can promote p53 ubiquitination have been identi¢ed.
The MDM2 gene is transcriptionally activated by p53, and
MDM2 protein can bind p53 and promote its ubiquitination
and degradation [10,11]. It has been suggested that MDM2
functions as an E3 ubiquitin ligase that transfers ubiquitin
directly to p53 [12,13]. Current models contend that DNA
damaging agents stabilize p53 by inhibiting MDM2-mediated
p53 ubiquitination (reviewed in [14]). Studies in support of
this model demonstrated that ionizing and UV radiation can
induce the phosphorylation of p53 N-terminal sites, and that
these phosphorylations can inhibit p53:MDM2 binding
[15,16]. In particular, phosphorylation at serine 15 (S15) or
20 (S20) diminished p53:MDM2 binding [16,17]. Further
studies demonstrated that high doses of UV radiation could
inhibit p53:MDM2 binding and p53 ubiquitination in transi-
ently transfected cells [18,19]. While phosphorylation is likely
to play a key role in p53 stability, other studies reported that
p53 proteins mutated in all potential N- and C-terminal phos-
phorylation sites could be stabilized in response to certain
DNA damaging stresses [20^22]. These ¢ndings suggest that
DNA damaging agents can stabilize p53 through alternative
mechanisms that do not involve p53 phosphorylation.
DNA alkylating agents promote monoadduct formation on
ring nitrogens or extra-cyclic oxygens of nucleotide bases,
which result in chromosomal loss or single base mutation
[23]. The toxic nature of DNA alkylating agents has resulted
in their use in various chemotherapy treatment regimens [24].
However, these agents are also carcinogenic and their use in
chemotherapy has been linked to the development of second-
ary leukemias and lymphomas [25]. Certain speci¢c alkylating
agents have been shown to signal an increase in p53 protein
levels [5,26], and to stimulate p53-dependent and p53-inde-
pendent apoptosis pathways [27,28]. The mechanisms by
which DNA alkylating agents signal an increase in p53 have
not been determined.
The purpose of the current study was to examine the e¡ect
of multiple DNA damaging agents, including DNA alkylating
agents, on the ubiquitination and stability of p53. p53 was
stabilized in response to each of the DNA damaging agents
tested. In contrast, the DNA alkylating agents mitomycin C
(MMC) and methylmethane sulfonate (MMS), as well as UV
radiation, signaled a marked decrease in the level of MDM2
mRNA and protein. This downregulation of MDM2 coin-
cided with decreased levels of ubiquitinated p53 and
p53:MDM2 binding complexes. Further, MMC, MMS and
UV radiation stabilized both wild-type p53 and a p53 mutant
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lacking all potential N-terminal phosphorylation sites in tran-
siently transfected cells, and this coincided with decreased
MDM2 protein levels. Importantly, p53 was not stabilized
in cells transiently overexpressing MDM2 that were treated
with MMC, MMS, or UV radiation. These results indicate
that the inhibition of ubiquitination and consequent stabiliza-
tion of p53 in response to MMC, MMS, and UV radiation
results at least in part from a downregulation of MDM2.
2. Materials and methods
2.1. Cell strains and tissue culture
RKO, MCF7, and SaOS-2 cells were grown in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% fetal bovine serum, 100 Wg/ml
penicillin and streptomycin. Radiation treatments were carried out in
the laboratory of radiobiology, Harvard School of Public Health.
Ionizing radiation (IR) was carried out using a 60CO gamma ray
source (US Nuclear) at a dose rate of 8.1 cGy/s. The UV source
was a specially constructed apparatus consisting of ¢ve UV bulbs
which delivered 254 nm light at a dose of 0.35 J/m2/s. 4-Nitroquino-
line-1-oxide (4NQO; 0.8 Wg/ml), cisplatin (CDDP; 50 WM), etoposide
(20 WM), MMC (100 WM), actinomycin D (30 ng/ml), MMS (100
Wg/ml), N-methyl-NP-nitro-N-nitrosoguanidine (MNNG; 0.5^4.0
Wg/ml), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; 50^200 WM)
and ethylmethane sulfonate (EMS; 50^200 Wg/ml) were added to the
growth medium where indicated. All these chemicals were from Sigma
Chemical.
2.2. SDS^PAGE, immunoprecipitations and immunoblots
Cells were rinsed with phosphate bu¡ered saline and scraped into
either radioimmunoprecipitation assay (RIPA) bu¡er (20 mM Tris
(pH 7.5), 2 mM EDTA, 150 mM NaCl, 1.0% Nonidet P-40, 1.0%
deoxycholate, 0.25% sodium dodecyl sulfate (SDS), 1 mM phenyl-
methylsulfonyl £uoride (PMSF), 2 Wg/ml aprotinin, 5 Wg/ml leupep-
tin), or lysis bu¡er (50 mM Tris (pH 7.5), 5 mM EDTA, 150 mM
NaCl, 0.5% NP-40, 1 mM PMSF, 2 Wg/ml aprotinin, 5 Wg/ml leupep-
tin). After harvest with RIPA bu¡er, cells were sonicated for 10 pulses
at setting 5, 50% output, with a Branson 450 soni¢er, and spun at
15 000Ug for 16 min to remove cellular debris. Lysates prepared in
lysis bu¡er were incubated on ice for 30 min with occasional light
vortexing, and spun at 15 000Ug for 15 min to remove cellular debris.
Protein extracts were examined by immunoblotting with the p53
monoclonal antibody DO-1 (Ab-6, Oncogene Science) or phospho-
p53 (at S15) antibody (New England Biolabs). The p53 blot was
reprobed with the MDM2 antibody SMP-14 (Santa Cruz Biotechnol-
ogy). For detection of ubiquitinated p53, lysates were immunopre-
cipitated using DO-1, and examined by immunoblotting with DO-1.
For coimmunoprecipitation analysis, p53 was immunoprecipitated us-
ing the p53 antibody PAb421 (Ab-1, Oncogene Science) followed by
immunoblotting with SMP-14.
2.3. Transfections
MCF7 cells were transfected using the calcium-phosphate method
[29] when the cells were approximately 80% con£uent. MCF7 cells
were transfected with either wild-type p53 or p53 N-term (S6, S9,
S15, T18, S20, S33 and S37 converted to alanine) alone, or cotrans-
fected with MDM2. 16 h after addition of the DNA precipitate, cells
were rinsed and refed. 8 h later, the cells were UV radiated (20 J/m2),
or treated with either MMS (100 Wg/ml) or MMC (100 WM), and then
cell lysates were prepared at 5 h after treatments. p53 levels were
monitored in the transfected cells by immunoblotting with DO-1 or
PAb1801 (Ab-2, Oncogene Science). MDM2 levels were detected by
immunoblotting with SMP-14. Detection of p53:ubiquitin conjugates
was carried out by immunoprecipitation of p53 with DO-1 followed
by immunoblot analysis with DO-1.
2.4. Northern blots
RNA was isolated using RNAzol B as described by the manufac-
turer (Tel-test, Inc.). 20 Wg (RKO) or 10 Wg (SaOS-2) of total RNA
was resolved in a formaldehyde^agarose gel and transferred to a ny-
lon membrane (Nytran, Schleicher and Schuell). Filters were hybrid-
ized with 32P-labeled human MDM2 cDNA, followed by two 15 min
washes at room temperature with 2USSC (150 mM NaCl, 15 mM
sodium citrate), 0.1% SDS, and one 30 min wash at 60‡C in 0.1USSC,
0.1% SDS.
3. Results
p53 is stabilized in response to various stresses, including
DNA damage, hypoxia, ribonucleotide depletion, and onco-
gene expression [14]. The wide variety of stresses which can
induce p53 raises the question as to the nature of the inducing
signal, and whether di¡erent agents stabilize p53 through
common mechanistic pathways. Current models suggest that
the stabilization of p53 in DNA damaged cells results from
phosphorylation of p53 N-terminal sites, which inhibits
Fig. 1. Levels of p53, p53 phosphorylated at serine 15 and MDM2
in RKO cells treated with various DNA damaging agents. A: Cells
were either untreated (no tr.), irradiated with 6.8 Gy ionizing radia-
tion (IR) or 20 J/m2 UV light for 5 h, or exposed to 4-nitroquino-
line-1-oxide (4NQO; 0.8 Wg/ml), cisplatin (CDDP; 50 WM), etopo-
side (Etop.; 20 WM), mitomycin C (MMC; 100 WM), actinomycin D
(Act. D; 30 ng/ml) or methylmethane sulfonate (MMS; 100 Wg/ml)
for 6 h. Cell extracts were then prepared and examined by immuno-
blot analysis with the p53-speci¢c antibody DO-1 (Ab-6), phospho-
p53 at serine 15 (S15-P) antibody, and MDM2-speci¢c antibody
SMP-14. B, C: Cells were either untreated (no tr.), or treated with
IR or UV radiation as in A, or exposed to the indicated concentra-
tions of N-methyl-NP-nitro-N-nitrosoguanidine (MNNG), 1,3-bis-
(2-chloroethyl)-1-nitrosourea (BCNU), or ethylmethane sulfonate
(EMS) for 6 h. Cell lysates were then examined by immunoblot
analysis for p53 and MDM2.
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p53:MDM2 binding, preventing MDM2 from promoting p53
ubiquitination (reviewed in [14]). In particular, DNA damage-
induced phosphorylation of p53 at S15 or S20 has been re-
ported to partially inhibit p53:MDM2 binding, suggesting
that phosphorylation at these sites may contribute to p53
stabilization [16,17]. In the current study, we examined p53
and MDM2 levels, as well as p53 ubiquitination and phos-
phorylation at S15 following exposure to various DNA dam-
aging agents.
RKO cells (p53 wild-type) were exposed to IR, UV radia-
tion, the UV mimetic 4NQO, CDDP, etoposide, actinomycin
D, or the DNA alkylating agents MMC and MMS. As shown
in Fig. 1A, p53 levels were increased in response to each
agent, indicating that the p53 protein was stabilized. Treated
cell lysates were also probed with an antibody directed against
p53 phosphorylated at serine 15. As shown in Fig. 1A, p53
was phosphorylated at S15 in response to each agent, though
to di¡erent extents. In these experiments, the extent of phos-
phorylation at S15 was not correlated with p53 levels. For
example, p53 was induced to a relatively high level following
IR and actinomycin D treatment, but phosphorylated at S15
relatively little, whereas p53 was both induced and phosphor-
ylated at S15 to relatively high levels following treatment with
4NQO, etoposide, and MMC.
MDM2 protein levels were also examined in the DNA dam-
aged cells (Fig. 1A). MDM2 levels were increased in cells
treated with IR, 4NQO, CDDP, etoposide and actinomycin
D. Interestingly, however, MDM2 levels were decreased in
response to UV radiation and the DNA alkylating agents
MMC and MMS compared to non-treated control cells. De-
creased MDM2 levels following UV treatment is consistent
with a previous report showing that UV radiation can inhibit
MDM2 gene transcription [30]. However, this represents the
¢rst indication that MMC and MMS can also signal a down-
regulation of MDM2. We next wished to determine whether
the downregulation of MDM2 is speci¢c to MMC and MMS,
or is also observed with other alkylating agents. Towards this
end, p53 and MDM2 levels were determined in cells treated
with the alkylating agents MNNG, BCNU (Fig. 1B) and
EMS (Fig. 1C). p53 and MDM2 levels were unchanged in
response to BCNU and EMS treatment. In contrast, p53
and MDM2 levels were both increased in cells treated with
increasing amounts of MNNG. These results suggest that the
downregulation of MDM2 protein levels is speci¢c to MMC
and MMS, and is not observed for all alkylating agents.
MDM2 mRNA levels were assessed to determine whether
the decreased MDM2 protein levels re£ected a decreased
MDM2 gene transcription. As shown in Fig. 2A, MDM2
mRNA levels were increased 6 h after exposure to IR, con-
sistent with p53 activating the MDM2 gene. In contrast,
MDM2 mRNA levels were decreased in UV-treated cells,
consistent with previous studies [30]. Importantly, MMC
and MMS also downregulated MDM2 mRNA levels, indicat-
ing that the decrease in MDM2 protein levels resulted from a
decrease in MDM2 gene transcription. MDM2 mRNA levels
were also decreased in SaOS-2 cells (p53 null) following MMC
or MMS treatment (Fig. 2B), indicating that this decrease can
occur in a p53-independent fashion.
Ubiquitin:p53 conjugates are detected as a ladder of p53
bands that are recognized by multiple p53 antibodies, and by
antibodies against ubiquitin [3,29]. Because MDM2 levels
Fig. 2. Northern blot analysis of MDM2 mRNA levels in RKO (A)
or SaOS-2 (B) cells treated with IR, UV light, MMC or MMS.
RKO cells or SaOS-2 cells, which lack wild-type p53, were either
untreated (no tr.), irradiated with 6.8 Gy IR for 0.5^7 h or 20 J/m2
UV light for 5 h, or exposed to 100 WM MMC or 100 Wg/ml MMS
for 6 h. Total RNA was then isolated and the Northern blot mem-
branes were probed with cDNA comprising MDM2 coding se-
quence. Levels of 18S and 28S ribosomal RNA were also indicated.
Fig. 3. Levels of ubiquitinated p53 and p53:MDM2 binding com-
plexes. A: RKO cells were either untreated (no tr.), or treated with
the indicated DNA damaging agents as in Fig. 1A. Cell lysates were
then prepared, and p53 was immunoprecipitated from 2.4 mg cell
lysates with the p53-speci¢c antibody DO-1 (Ab-6). The immuno-
precipitates were examined for ubiquitinated p53 (p53-Ubn) by im-
munoblot analysis with DO-1. Asterisk indicates the position of the
Ab heavy chain used in the immunoprecipitation. B: RKO cells
were either untreated (no tr.), or treated with the indicated DNA
damaging agents as above. p53 was immunoprecipitated from 6.4 mg
cell lysates using the p53-speci¢c antibody PAb421 (Ab-1). The im-
munoprecipitates were then examined by immunoblot analysis with
the MDM2-speci¢c antibody SMP-14.
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were decreased by speci¢c DNA damaging agents, we wished
to determine whether ubiquitinated p53 levels were also de-
creased in response to these agents. p53 was immunoprecipi-
tated from RKO cells treated with various DNA damaging
agents and examined for ubiquitinated p53 with a p53 anti-
body (Fig. 3A). A characteristic ladder of ubiquitin:p53 con-
jugates was detected in untreated RKO cells. The levels of
ubiquitinated p53 were increased following treatment with
IR, 4NQO, CDDP, etoposide and actinomycin D (Fig. 3A),
consistent with the increased MDM2 protein levels in re-
sponse to these treatments (Fig. 1A). In contrast, ubiquiti-
nated p53 levels were decreased in response to UV, MMC
and MMS (Fig. 3A), consistent with the decreased MDM2
levels in cells treated with these agents. As shown in Fig.
3B, the level of p53:MDM2 binding complexes was similarly
increased in response to IR, 4NQO, CDDP, etoposide and
actinomycin D, and decreased in response to UV radiation,
MMC and MMS (Fig. 3B).
Our results suggested that MMC, MMS, and UV radiation
stabilize p53 by signaling a decrease in MDM2 protein levels,
and a subsequent loss of p53 ubiquitination. In this case,
maintaining MDM2 expression would be expected to block
the stabilization of p53 in MMC-, MMS-, and UV-treated
cells. To test this, cells were mock-transfected or transfected
with increasing amounts of an MDM2 expression DNA, and
subsequently exposed to UV radiation, MMC or MMS. As
shown in Fig. 4A, each of these agents caused an increase in
p53 levels in mock-transfected cells, coincident with a decrease
in MDM2. In contrast, MDM2 was maintained at high levels
in MMC-, MMS-, or UV-treated cells transfected with
MDM2 expression DNA, and in this case the induction of
p53 was partially inhibited. These results are consistent with
the downregulation of MDM2 contributing to the stabiliza-
tion of p53 in the MMC-, MMS-, and UV-treated cells.
Cells were next transfected with either wild-type p53 alone,
or cotransfected with MDM2, and then treated with UV,
MMC or MMS (Fig. 4B). The transfected p53 protein was
stabilized and its levels increased following treatment of cells
transfected with p53 alone, and this was coincident with de-
creased MDM2 expression. In contrast, overexpression of
MDM2 inhibited stabilization of the transfected p53 protein
(Fig. 4B). Further, ubiquitinated p53 levels were decreased in
the UV-, MMC-, and MMS-treated cells transfected with p53
alone, but remained elevated in cells coexpressing p53 and
MDM2 (Fig. 4B). These results indicate that MMC, MMS
and UV radiation stabilized the transfected p53 protein by
reducing MDM2 protein levels, and causing a consequent
decrease in p53 ubiquitination.
Finally, we wished to determine whether MMC and MMS
could stabilize p53 in a manner independent of phosphoryla-
tion in p53 N-terminus. Towards this end, cells were trans-
fected with an expression DNA encoding a p53 mutant (re-
ferred to as p53 N-term) which lacks all potential N-terminal
phosphorylation sites (S6, S9, S15, T18, S20, S33 and S37).
Levels of p53 N-term were assessed in either untreated cells,
or in cells exposed to MMC, MMS, or UV radiation. As
shown in Fig. 5, levels of p53 N-term were increased in trans-
fected cells following treatment with these agents, coincident
with a decrease in MDM2 levels. These results indicate that
Fig. 4. A: Levels of p53 and MDM2 in cells mock-transfected or
overexpressed with MDM2. MCF7 cells were mock-transfected or
transfected with either 10 or 20 Wg of MDM2 DNA. 24 h later, the
cells were irradiated with 20 J/m2 UV light, or treated with either
100 Wg/ml MMS or 100 WM MMC. 5 h later, cell lysates were pre-
pared. p53 levels were monitored by immunoblot analysis with DO-
1 (Ab-6). MDM2 levels were monitored by stripping the p53 blot
and reprobing with the MDM2 antibody SMP-14. B: Levels of p53,
MDM2 and ubiquitinated p53 in cells transiently transfected with
wild-type (wt) p53 with or without MDM2. MCF7 cells were mock-
transfected, or transfected with 4 Wg of wt p53 alone, or wt p53
(4 Wg) and MDM2 (10 Wg). 24 h later, the cells were treated with
UV light (20 J/m2), MMS (100 Wg/ml) or MMC (100 WM), and cell
lysates were prepared 5 h later. p53 and MDM2 levels were deter-
mined by immunoblot analysis with the DO-1 and SMP-14 antibod-
ies. Levels of p53:ubiquitin conjugates (p53-Ubn) were determined
by immunoprecipitation of p53 with p53-speci¢c antibody DO-1 fol-
lowed by immunoblot analysis with DO-1. Asterisk indicates the po-
sition of the Ab heavy chain.
Fig. 5. Levels of p53 and MDM2 in cells transiently transfected
with N-terminal phosphorylation mutant (N-term) of p53 with or
without MDM2. MCF7 cells were mock-transfected, or transfected
with p53 N-term (10 Wg) only, or p53 N-term (10 Wg) and MDM2
(10 Wg) DNA. 24 h later, the cells were treated with UV light (20
J/m2), MMS (100 Wg/ml) or MMC (100 WM). 5 h later, cell lysates
were prepared. p53 levels were monitored by immunoblot analysis
with PAb1801 (Ab-2). MDM2 levels were monitored by stripping
the p53 blot and reprobing with the MDM2 antibody SMP-14.
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the ability of MMC, MMS, and UV radiation to stabilize p53
does not require phosphorylation of p53 N-terminal sites.
Importantly, cotransfection of MDM2 inhibited the stabiliza-
tion of p53 N-term in response to MMC, MMS, and UV
treatment, indicating that the stabilization of p53 N-term re-
sulted from a downregulation of MDM2.
4. Discussion
The mechanism by which DNA damaging agents stabilize
p53 has not been fully clari¢ed. Two proteolytic pathways
have been implicated in the degradation of p53: the calpain
proteolytic pathway [31,32], and the ubiquitin-dependent pro-
teolytic pathway [10,11,18,29]. Given that p53 can be de-
graded through these pathways, one possibility is that DNA
damaging agents signal an inhibition of p53 degradation
through either the calpain pathway, the ubiquitin pathway,
or both. The e¡ect of DNA damaging agents on the cal-
pain-mediated degradation of p53 has not been assessed.
However, several studies have suggested that DNA damaging
agents can inhibit p53:MDM2 binding and MDM2-depen-
dent p53 ubiquitination. For example, IR and UV radiation
can induce the phosphorylation of p53 N-terminal sites, and
this phosphorylation can inhibit p53:MDM2 binding [17,33].
These ¢ndings and others have led to a model in which
MDM2 binds p53 under normal conditions and promotes
its ubiquitination and subsequent degradation. In response
to DNA damage, phosphorylation of p53 leads to an inhibi-
tion of MDM2 binding, and thus stabilization of the p53
protein. Further support for this model comes from studies
in which high doses of UV radiation inhibited p53 ubiquiti-
nation and p53:MDM2 binding in transfected and non-trans-
fected cells [18,19].
While phosphorylation of p53 is likely to be an important
determinant of p53 stability, the involvement of speci¢c phos-
phorylation events has not been fully determined. In fact,
phosphorylation of N- and C-terminal sites in p53 is not ab-
solutely required for p53 to be stabilized in response to certain
DNA damaging agents. For example, Ashcroft et al. [21] re-
ported that a p53 protein mutated in all potential N- as well
as C-terminal phosphorylation sites remained susceptible to
stabilization induced by UV radiation and actinomycin D.
Similar results were obtained using IR, UV and actinomycin
D by Blattner et al. [22]. These studies indicate that certain
DNA damaging agents can stabilize p53 through alternative
pathways that are independent of p53 phosphorylation. While
the identity of such alternative pathways has not yet been
fully determined, downregulation of MDM2 expression has
been suggested as a likely secondary mechanism by which
UV radiation can stabilize p53 [3,19].
The current report demonstrates that the DNA alkylating
agents MMC and MMS can stabilize p53 while simultane-
ously signaling a decrease in MDM2 mRNA and protein lev-
els. Recent reports indicate that MDM2 is phosphorylated in
response to certain DNA damaging treatments, and that this
phosphorylation inhibits recognition by speci¢c monoclonal
antibodies, leading to the impression that MDM2 levels are
decreased [34]. It is unknown at present if MDM2 is phos-
phorylated in response to MMC and MMS. However, the fact
that MDM2 mRNA levels are decreased in response to these
agents indicates that the decrease in MDM2 observed re£ects
a true decrease in MDM2 protein levels. This report repre-
sents the ¢rst demonstration that MMC and MMS have a
speci¢c e¡ect on MDM2 gene transcription, and indicates
that the stabilization of p53 in response to these agents is
likely to involve the downregulation of MDM2 mRNA and
protein levels. Further, the experiment using p53 N-term in-
dicates for the ¢rst time that stabilization of p53 by MMC
and MMS does not require p53 phosphorylation at N-termi-
nus.
It is perhaps interesting that MDM2 protein levels, as well
as levels of ubiquitinated p53, were increased in response to
certain DNA damaging agents but decreased in response to
others. These ¢ndings indicate that the stabilization of p53 in
response to various DNA damaging agents is not likely to
occur through a single pathway, but instead may involve mul-
tiple mechanisms that are unique to the individual DNA dam-
aging agent being tested. The degradation of p53 by MDM2
involves several steps which could potentially be regulated in
response to DNA damage, including MDM2 expression, the
interaction of MDM2 with ubiquitin system enzymes,
p53:MDM2 complex formation, the export of p53 from the
nucleus to the cytoplasm, and the degradation of ubiquiti-
nated p53 by the proteasome. It remains to be seen whether
any or all of these steps are regulated in a DNA damaged cell.
Clinically, MDM2 appears to be a promising target of can-
cer therapy, since overexpression of MDM2 has been corre-
lated with poor prognosis or advanced stage in several cancers
[35,36]. Therapy aimed at inactivating MDM2 could be used
to reestablish p53 activity in cancers that have a high percent-
age of cases where p53 is wild-type, including leukemia, neu-
roblastoma, and breast cancer [37]. In these cases the chemo-
therapeutic alkylating agents such as MMC may be useful
treatment adjuvants due to the fact that they mediate a down-
regulation of MDM2 protein.
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